Martin Nicklasson

Martin Nicklasson, Chairman, was born in 1955 and is a Swedish citizen. He is a certified pharmacist and holds a PhD in pharmaceutical technology from the University of Uppsala, Sweden. He is Associate Professor at the Department of Pharmaceutics, University of Uppsala.

Nicklasson held a number of leadership positions in commercial operations and drug development within Astra and Kabi Pharmacia before joining AstraZeneca Plc. From 1999 to 2007 he held various Executive Vice President positions at AstraZeneca Plc., and acted as a member of the Executive Committee. From 2007 to 2010, he was the President and CEO of Biovitrum AB and Swedish Orphan Biovitrum AB, one of Europe's largest specialty pharma companies focusing on rare diseases.

He is currently a senior partner at Nicklasson Life Science AB, an independent consultancy and advisory company to the pharmaceutical and biotechnology sector. Nicklasson is member of the board of EffRx Pharmaceuticals SA (Switzerland), Biocrine AB (Sweden), PledPharma AB (Sweden), Premier Research Group Ltd. (UK) and chairman of the board of directors of Farma Holding AS (Norway), Orexo AB (Sweden) and Zealand Pharma A/S (Denmark).

He is member of the Royal Swedish Academy of Engineering Sciences, the Royal Bachelors' Club (Sweden), the Pharmaceutical Faculty Council of the University of Uppsala, and the Swedish Academy of Pharmaceutical Sciences.

Martin Nicklasson is the Director of the Board at Basilea Pharmaceutica, based in Europe. With a background in Biotechnology, Martin Nicklasson has a rich history of leadership and innovation.Martin Nicklasson studied PhD Pharmaceutical Technology at Uppsala University. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.